文献速递淋巴瘤

EB病毒编码的EBNA2通过诱导miR-24下调B细胞淋巴瘤中的ICOSL

Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
PubMed 文献 · Blood · 2024-01-01

研究探讨EBV编码的EBNA2是否影响B细胞淋巴瘤中ICOSL的表达。在病毒感染和EBNA2转染的B淋巴瘤细胞中ICOSL表达降低,机制为EBNA2诱导miR-24增加,ICOSL是miR-24的真实靶点。抗miR-24转染可恢复ICOSL表达并增强肿瘤免疫原性,同时升高c-MYC并增加凋亡。EBNA2阳性DLBCL活检标本中ICOSL低表达、miR-24高表达。作者认为miR-24是EBV相关淋巴瘤的潜在治疗靶点。

要点

  • EBNA2通过诱导miR-24下调ICOSL表达,减少T细胞对肿瘤细胞的识别。
  • 抗miR-24转染可恢复ICOSL表达并增强混合淋巴细胞反应中的肿瘤免疫原性。
  • EBNA2阳性DLBCL活检标本中ICOSL低表达、miR-24高表达,与体外数据一致。

核心结论

  • 作者认为EBV通过EBNA2诱导miR-24减少ICOSL表达以逃避宿主免疫应答,同时维持促增殖的c-MYC水平。
  • 这些数据确定miR-24为EBV相关淋巴瘤的潜在治疗相关靶点。

研究设计与样本

  • 研究采用病毒感染的B淋巴瘤细胞和EBNA2转染的B淋巴瘤细胞进行体外实验,并使用ICOSL 3'非翻译区荧光素酶报告系统验证靶点。
  • 研究分析了EBNA2阳性DLBCL活检标本中ICOSL和miR-24的表达。

主要发现

  • 在病毒感染的B淋巴瘤细胞和EBNA2转染的B淋巴瘤细胞中,ICOSL表达降低。
  • EBNA2通过增加microRNA-24(miR-24)导致ICOSL表达降低,荧光素酶报告系统验证ICOSL是miR-24的真实靶点。
  • 在EBNA2表达的淋巴瘤细胞中转染抗miR-24分子可恢复ICOSL表达,并在混合淋巴细胞反应中增加肿瘤免疫原性。
  • 在EBNA2表达的DLBCL细胞中减少miR-24进一步升高c-MYC并增加凋亡。
  • EBNA2阳性DLBCL活检标本中ICOSL低表达、miR-24高表达,与体外数据一致。

临床怎么用

  • 作者认为miR-24是EBV相关淋巴瘤的潜在治疗相关靶点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematological malignancies such as Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and diffuse large B-cell lymphoma (DLBCL) cause significant morbidity in humans. A substantial number of these lymphomas, particularly HL and DLBCLs have poorer prognosis because of their association with Epstein-Barr virus (EBV). Our earlier studies have shown that EBV-encoded nuclear antigen (EBNA2) upregulates programmed cell death ligand 1 in DLBCL and BLs by downregulating microRNA-34a. Here, we investigated whether EBNA2 affects the inducible costimulator (ICOS) ligand (ICOSL), a molecule required for efficient recognition of tumor cells by T cells through the engagement of ICOS on the latter. In virus-infected and EBNA2-transfected B-lymphoma cells, ICOSL expression was reduced. Our investigation of the molecular mechanisms revealed that this was due to an increase in microRNA-24 (miR-24) by EBNA2. By using ICOSL 3' untranslated region-luciferase reporter system, we validated that ICOSL is an authentic miR-24 target. Transfection of anti-miR-24 molecules in EBNA2-expressing lymphoma cells reconstituted ICOSL expression and increased tumor immunogenicity in mixed lymphocyte reactions. Because miR-24 is known to target c-MYC, an oncoprotein positively regulated by EBNA2, we analyzed its expression in anti-miR-24 transfected lymphoma cells. Indeed, the reduction of miR-24 in EBNA2-expressing DLBCL further elevated c-MYC and increased apoptosis. Consistent with the in vitro data, EBNA2-positive DLBCL biopsies expressed low ICOSL and high miR-24. We suggest that EBV evades host immune responses through EBNA2 by inducing miR-24 to reduce ICOSL expression, and for simultaneous rheostatic maintenance of proproliferative c-MYC levels. Overall, these data identify miR-24 as a potential therapeutically relevant target in EBV-associated lymphomas.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Leopizzi M, Mundo L, Messina E, et al. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma. Blood. 2024. PMID: 37847858. doi:10.1182/blood.2023021346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。